Transition Therapeutics Inc. (NASDAQ:TTHI)
| CAPS Rating |
|
|---|---|
| Open | $2.11 |
| Previous Close | $2.24 |
| Daily Range | $1.90 - $2.15 |
| 52-Week Range | $1.15 - $5.49 |
| Market Cap | $45.27M |
| P/E Ratio | 2.90 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 103,776 |
| Average Daily Volume | 0 |
TTHI
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
TTHI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
TTHI News and Commentary
- Elan, Lonza in Supply Deal - Analyst Blog – NASDAQ
- Life Sciences Companies Raise Record Amounts of Capital – SeekingAlpha
- UPDATE: Transition Halts Development Of Lead Diabetes Drug – SmartMoney
- Transition Halts Development Of Lead Diabetes Candidate – SmartMoney
- Transition Buys Rights To Eli Lilly Diabetes Compounds – SmartMoney
- Sniffing around for more bottoms – Blog at The Motley Fool
- Forget the Higher Doses – The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
- Idenix Pharmaceuticals Shares Dropped: What You Need to Know – The Motley Fool
- What's Going on With These Biotech Stocks? – The Motley Fool
- Gilead Sciences Shares Surged: What You Need to Know – The Motley Fool
RSS Headlines
Fool UK
